Phenobarbital
Sezaby (phenobarbital) is a small molecule pharmaceutical. Phenobarbital was first approved as Sezaby on 2022-11-17. It is used to treat benign neonatal epilepsy, febrile seizures, hyperbilirubinemia, partial epilepsies, and tonic-clonic epilepsy in the USA. It is known to target nuclear receptor subfamily 1 group I member 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Sezaby
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Phenobarbital sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SEZABY | Sun Pharmaceutical Industries | N-215910 RX | 2022-11-17 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| donnatal | unapproved drug other | 2024-12-05 |
| donnatal extentabs | unapproved drug other | 2011-10-17 |
| phenobarbital | unapproved drug other | 2026-06-22 |
| phenobarbital oral solution | unapproved drug other | 2025-12-29 |
| phenobarbital sodium | unapproved drug other | 2025-12-17 |
| phenobarbital with belladonna alkaloids | unapproved drug other | 2020-08-05 |
| phenobarbital, hyoscyamine sulfate, atropine sulfate and scopolamine hydrobromide | unapproved drug other | 2023-01-10 |
| phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide | unapproved drug other | 2023-01-12 |
| phenohytro | unapproved drug other | 2026-05-19 |
| quadrapax | unapproved drug other | 2011-09-13 |
Show 2 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PHENOBARBITAL SODIUM, SEZABY, SUN PHARM INDS INC | |||
| 2029-11-17 | ODE-414 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Phenobarbital Sodium, Sezaby, Sun Pharm Inds Inc | |||
| 11857683 | 2042-04-07 | DP | U-3779 |
HCPCS
Code | Description |
|---|---|
| J2560 | Injection, phenobarbital sodium, up to 120 mg |
Clinical
Clinical Trials
361 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 6 | 50 | 15 | 4 | 45 | 116 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | 1 | 1 | 25 | 28 |
| Seizures | D012640 | — | G40.4 | 4 | 5 | 5 | 3 | 8 | 22 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | 2 | 4 | 2 | 6 | 14 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | — | 2 | 11 | 13 |
| Pathologic constriction | D003251 | — | — | — | — | — | 1 | 10 | 11 |
| Syndrome | D013577 | — | — | — | 1 | 1 | 2 | 6 | 10 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | 2 | 6 | 8 |
| Coronary stenosis | D023921 | EFO_1000882 | — | — | — | — | 1 | 7 | 8 |
| Male breast neoplasms | D018567 | — | — | — | 2 | 1 | 1 | 3 | 7 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | — | — | 3 | 9 | 1 | — | 5 | 15 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 2 | — | 6 | 8 |
| Status epilepticus | D013226 | EFO_0008526 | G41 | — | 1 | 4 | — | — | 5 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 2 | — | 3 | 5 |
| Brain stem neoplasms | D020295 | EFO_1001767 | — | — | 1 | 1 | — | — | 2 |
| Breast diseases | D001941 | — | N60-N65 | — | 1 | 1 | — | 1 | 2 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | 1 | — | 1 | 2 |
| Rectal neoplasms | D012004 | — | — | — | — | 1 | — | 1 | 2 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 2 | — | — | 2 |
| Drug therapy | D004358 | — | — | — | 1 | 1 | — | — | 1 |
Show 17 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 3 | — | — | 7 | 10 |
| Neoplasms | D009369 | — | C80 | 1 | 3 | — | — | 4 | 8 |
| Glioblastoma | D005909 | EFO_0000515 | — | 5 | 2 | — | — | — | 6 |
| Gliosarcoma | D018316 | — | — | 5 | 2 | — | — | — | 6 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | 4 | 5 |
| Adenoma | D000236 | — | — | — | 1 | — | — | 4 | 5 |
| Astrocytoma | D001254 | EFO_0000271 | — | 4 | 1 | — | — | — | 4 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | 3 | 4 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | 1 | — | — | — | 2 |
| Central nervous system neoplasms | D016543 | — | — | 1 | 2 | — | — | — | 2 |
Show 17 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 2 | — | — | — | 3 | 5 |
| Glioma | D005910 | EFO_0000520 | — | 4 | — | — | — | — | 4 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | 3 | 4 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | 2 | 3 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 1 | — | — | — | 2 | 3 |
| Dentin dysplasia | D003805 | — | K00.5 | 1 | — | — | — | — | 1 |
| Neutropenia | D009503 | — | D70 | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
Show 19 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 18 | 18 |
| Coronary disease | D003327 | — | — | — | — | — | — | 12 | 12 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | — | 9 | 9 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 5 | 5 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | — | — | 5 | 5 |
| Coronary restenosis | D023903 | EFO_0004224 | — | — | — | — | — | 4 | 4 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 4 | 4 |
| Colonic polyps | D003111 | — | K63.5 | — | — | — | — | 4 | 4 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | — | 3 | 3 |
| Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | — | — | — | 3 | 3 |
Show 135 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Phenobarbital |
| INN | phenobarbital |
| Description | Phenobarbital is a member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups. It has a role as an anticonvulsant, a sedative, an excitatory amino acid antagonist and a drug allergen. |
| Classification | Small molecule |
| Drug class | barbituric acid derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC1(c2ccccc2)C(=O)NC(=O)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 50-06-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL40 |
| ChEBI ID | 8069 |
| PubChem CID | 4763 |
| DrugBank | DB01174 |
| UNII ID | YQE403BP4D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NR1I2
NR1I2
Organism
Homo sapiens
Gene name
NR1I2
Gene synonyms
PXR
NCBI Gene ID
Protein name
nuclear receptor subfamily 1 group I member 2
Protein synonyms
Orphan nuclear receptor PAR1, Orphan nuclear receptor PXR, Pregnane X receptor, Steroid and xenobiotic receptor, SXR
Uniprot ID
Mouse ortholog
Nr1i2 (18171)
nuclear receptor subfamily 1 group I member 2 (O54915)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Phenobarbital
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Phenobarbital
+
Ergotamine
+
Atropa belladonna
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 164,915 documents
View more details
Safety
Black-box Warning
Black-box warning for: Sezaby
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,560 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use